A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial

Tatsuo Ichinohe, Yoshiaki Kuroda, Shinichiro Okamoto, Kosei Matsue, Shinsuke Iida, Kazutaka Sunami, Takuya Komeno, Kenshi Suzuki, Kiyoshi Ando, Masafumi Taniwaki, Kensei Tobinai, Takaaki Chou, Hitomi Kaneko, Hiromi Iwasaki, Chie Uemura, Hiromi Tamakoshi, Mohamed H. Zaki, Thomas Doerr, Shotaro Hagiwara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 and 3 trials. However, these trials enrolled very few Asian patients. Methods: This phase 2 study investigated pomalidomide plus low-dose dexamethasone in 36 Japanese patients with RRMM after ≥2 prior therapies. Results: Patients enrolled in the study had a relatively high disease burden (81 % Durie-Salmon stage II or III) and were heavily pretreated (median, 6.5 prior antimyeloma regimens). The overall response rate was 42 % (1 patient with complete response and 14 with partial response), with an additional 44 % (16 patients) achieving stable disease (SD). Response rates in patients aged ≤65 years and >65 years were 47 and 35 %, respectively. None of the five patients with extramedullary disease achieved a response, with three of them maintaining SD of short duration. Median progression-free survival was 10.1 months after a 7.7-month median follow-up, and the median overall survival was not reached. The most frequent grade ≥3 adverse events (AEs) were neutropenia (64 %), anemia (42 %), and thrombocytopenia (31 %). The most frequent nonhematologic grade ≥3 AEs were pneumonia and decreased appetite (8 % each). Adverse events in patients aged >65 years were similar to those in patients aged ≤65 years, except for a higher rate of grade ≥3 pneumonia. Conclusions: Collectively, the results of this study demonstrate that pomalidomide plus low-dose dexamethasone is an effective and safe treatment for Japanese patients with RRMM, although careful attention needs to be paid to serious infections. Trial registration: Clinicaltrials.gov NCT02011113

Original languageEnglish
Article number11
JournalExperimental Hematology and Oncology
Volume5
Issue number1
DOIs
Publication statusPublished - 2016 Apr 18

Fingerprint

Multiple Myeloma
Dexamethasone
Pneumonia
pomalidomide
Salmon
Appetite
Neutropenia
Thrombocytopenia
Disease-Free Survival
Anemia
Safety
Survival
Therapeutics
Infection

Keywords

  • Asian
  • Japan
  • Phase 2
  • Plasmacytoma
  • Pomalidomide
  • Relapsed/refractory multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma : The Japanese MM-011 trial. / Ichinohe, Tatsuo; Kuroda, Yoshiaki; Okamoto, Shinichiro; Matsue, Kosei; Iida, Shinsuke; Sunami, Kazutaka; Komeno, Takuya; Suzuki, Kenshi; Ando, Kiyoshi; Taniwaki, Masafumi; Tobinai, Kensei; Chou, Takaaki; Kaneko, Hitomi; Iwasaki, Hiromi; Uemura, Chie; Tamakoshi, Hiromi; Zaki, Mohamed H.; Doerr, Thomas; Hagiwara, Shotaro.

In: Experimental Hematology and Oncology, Vol. 5, No. 1, 11, 18.04.2016.

Research output: Contribution to journalArticle

Ichinohe, T, Kuroda, Y, Okamoto, S, Matsue, K, Iida, S, Sunami, K, Komeno, T, Suzuki, K, Ando, K, Taniwaki, M, Tobinai, K, Chou, T, Kaneko, H, Iwasaki, H, Uemura, C, Tamakoshi, H, Zaki, MH, Doerr, T & Hagiwara, S 2016, 'A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial', Experimental Hematology and Oncology, vol. 5, no. 1, 11. https://doi.org/10.1186/s40164-016-0040-7
Ichinohe, Tatsuo ; Kuroda, Yoshiaki ; Okamoto, Shinichiro ; Matsue, Kosei ; Iida, Shinsuke ; Sunami, Kazutaka ; Komeno, Takuya ; Suzuki, Kenshi ; Ando, Kiyoshi ; Taniwaki, Masafumi ; Tobinai, Kensei ; Chou, Takaaki ; Kaneko, Hitomi ; Iwasaki, Hiromi ; Uemura, Chie ; Tamakoshi, Hiromi ; Zaki, Mohamed H. ; Doerr, Thomas ; Hagiwara, Shotaro. / A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma : The Japanese MM-011 trial. In: Experimental Hematology and Oncology. 2016 ; Vol. 5, No. 1.
@article{66e4fe2b3a8d4a5aa26ace7fdf762fb5,
title = "A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial",
abstract = "Background: The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 and 3 trials. However, these trials enrolled very few Asian patients. Methods: This phase 2 study investigated pomalidomide plus low-dose dexamethasone in 36 Japanese patients with RRMM after ≥2 prior therapies. Results: Patients enrolled in the study had a relatively high disease burden (81 {\%} Durie-Salmon stage II or III) and were heavily pretreated (median, 6.5 prior antimyeloma regimens). The overall response rate was 42 {\%} (1 patient with complete response and 14 with partial response), with an additional 44 {\%} (16 patients) achieving stable disease (SD). Response rates in patients aged ≤65 years and >65 years were 47 and 35 {\%}, respectively. None of the five patients with extramedullary disease achieved a response, with three of them maintaining SD of short duration. Median progression-free survival was 10.1 months after a 7.7-month median follow-up, and the median overall survival was not reached. The most frequent grade ≥3 adverse events (AEs) were neutropenia (64 {\%}), anemia (42 {\%}), and thrombocytopenia (31 {\%}). The most frequent nonhematologic grade ≥3 AEs were pneumonia and decreased appetite (8 {\%} each). Adverse events in patients aged >65 years were similar to those in patients aged ≤65 years, except for a higher rate of grade ≥3 pneumonia. Conclusions: Collectively, the results of this study demonstrate that pomalidomide plus low-dose dexamethasone is an effective and safe treatment for Japanese patients with RRMM, although careful attention needs to be paid to serious infections. Trial registration: Clinicaltrials.gov NCT02011113",
keywords = "Asian, Japan, Phase 2, Plasmacytoma, Pomalidomide, Relapsed/refractory multiple myeloma",
author = "Tatsuo Ichinohe and Yoshiaki Kuroda and Shinichiro Okamoto and Kosei Matsue and Shinsuke Iida and Kazutaka Sunami and Takuya Komeno and Kenshi Suzuki and Kiyoshi Ando and Masafumi Taniwaki and Kensei Tobinai and Takaaki Chou and Hitomi Kaneko and Hiromi Iwasaki and Chie Uemura and Hiromi Tamakoshi and Zaki, {Mohamed H.} and Thomas Doerr and Shotaro Hagiwara",
year = "2016",
month = "4",
day = "18",
doi = "10.1186/s40164-016-0040-7",
language = "English",
volume = "5",
journal = "Experimental Hematology and Oncology",
issn = "2162-3619",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma

T2 - The Japanese MM-011 trial

AU - Ichinohe, Tatsuo

AU - Kuroda, Yoshiaki

AU - Okamoto, Shinichiro

AU - Matsue, Kosei

AU - Iida, Shinsuke

AU - Sunami, Kazutaka

AU - Komeno, Takuya

AU - Suzuki, Kenshi

AU - Ando, Kiyoshi

AU - Taniwaki, Masafumi

AU - Tobinai, Kensei

AU - Chou, Takaaki

AU - Kaneko, Hitomi

AU - Iwasaki, Hiromi

AU - Uemura, Chie

AU - Tamakoshi, Hiromi

AU - Zaki, Mohamed H.

AU - Doerr, Thomas

AU - Hagiwara, Shotaro

PY - 2016/4/18

Y1 - 2016/4/18

N2 - Background: The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 and 3 trials. However, these trials enrolled very few Asian patients. Methods: This phase 2 study investigated pomalidomide plus low-dose dexamethasone in 36 Japanese patients with RRMM after ≥2 prior therapies. Results: Patients enrolled in the study had a relatively high disease burden (81 % Durie-Salmon stage II or III) and were heavily pretreated (median, 6.5 prior antimyeloma regimens). The overall response rate was 42 % (1 patient with complete response and 14 with partial response), with an additional 44 % (16 patients) achieving stable disease (SD). Response rates in patients aged ≤65 years and >65 years were 47 and 35 %, respectively. None of the five patients with extramedullary disease achieved a response, with three of them maintaining SD of short duration. Median progression-free survival was 10.1 months after a 7.7-month median follow-up, and the median overall survival was not reached. The most frequent grade ≥3 adverse events (AEs) were neutropenia (64 %), anemia (42 %), and thrombocytopenia (31 %). The most frequent nonhematologic grade ≥3 AEs were pneumonia and decreased appetite (8 % each). Adverse events in patients aged >65 years were similar to those in patients aged ≤65 years, except for a higher rate of grade ≥3 pneumonia. Conclusions: Collectively, the results of this study demonstrate that pomalidomide plus low-dose dexamethasone is an effective and safe treatment for Japanese patients with RRMM, although careful attention needs to be paid to serious infections. Trial registration: Clinicaltrials.gov NCT02011113

AB - Background: The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 and 3 trials. However, these trials enrolled very few Asian patients. Methods: This phase 2 study investigated pomalidomide plus low-dose dexamethasone in 36 Japanese patients with RRMM after ≥2 prior therapies. Results: Patients enrolled in the study had a relatively high disease burden (81 % Durie-Salmon stage II or III) and were heavily pretreated (median, 6.5 prior antimyeloma regimens). The overall response rate was 42 % (1 patient with complete response and 14 with partial response), with an additional 44 % (16 patients) achieving stable disease (SD). Response rates in patients aged ≤65 years and >65 years were 47 and 35 %, respectively. None of the five patients with extramedullary disease achieved a response, with three of them maintaining SD of short duration. Median progression-free survival was 10.1 months after a 7.7-month median follow-up, and the median overall survival was not reached. The most frequent grade ≥3 adverse events (AEs) were neutropenia (64 %), anemia (42 %), and thrombocytopenia (31 %). The most frequent nonhematologic grade ≥3 AEs were pneumonia and decreased appetite (8 % each). Adverse events in patients aged >65 years were similar to those in patients aged ≤65 years, except for a higher rate of grade ≥3 pneumonia. Conclusions: Collectively, the results of this study demonstrate that pomalidomide plus low-dose dexamethasone is an effective and safe treatment for Japanese patients with RRMM, although careful attention needs to be paid to serious infections. Trial registration: Clinicaltrials.gov NCT02011113

KW - Asian

KW - Japan

KW - Phase 2

KW - Plasmacytoma

KW - Pomalidomide

KW - Relapsed/refractory multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84978023352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978023352&partnerID=8YFLogxK

U2 - 10.1186/s40164-016-0040-7

DO - 10.1186/s40164-016-0040-7

M3 - Article

AN - SCOPUS:84978023352

VL - 5

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

SN - 2162-3619

IS - 1

M1 - 11

ER -